Skip to main content

Dupilumab-associated eosinophilia in chronic rhinosinusitis with nasal polyps: frequency, temporal dynamics, predictors, and clinical consequences-a systematic review and meta-analysis

In brief

About 8% of dupilumab-treated sinus patients developed high eosinophils

A meta-analysis found high blood eosinophil counts in 7.9% of dupilumab-treated patients with nasal polyps, though estimates varied widely and the evidence was rated very uncertain. Counts generally rose in the first 1 to 6 months then declined; severe organ complications and permanent treatment changes were uncommon, but no validated monitoring schedule or risk threshold exists.

Journal
Frontiers in immunology (Q1)
Published
3 November 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Sara Torretta, Lorenzo Cavaleri, Anna Cozzi, Silvia Maria Cavalera, Ludovica Battilocchi
PMID
43047528
DOI
10.3389/fimmu.2026.2004832

Why clinicians should know about it

  • Picked for Immunology and Allergy (paper of the day, 21 November 2026): Quantifies eosinophilia and complications during dupilumab treatment

Abstract

BACKGROUND: Dupilumab may cause a treatment-emergent rise in circulating eosinophils, but the frequency, temporal pattern, predictors, and clinical consequences of hypereosinophilia (HE) in chronic rhinosinusitis with nasal polyps (CRSwNP) remain incompletely defined. METHODS: We performed a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 systematic review and meta-analysis of PubMed/MEDLINE and Embase.com studies reporting post-treatment circulating eosinophil outcomes in dupilumab-treated CRSwNP. Potentially overlapping reports were linked at the cohort and outcome level. The primary outcome was post-treatment HE ≥1,500 cells/µL, synthesized using a binomial-normal random-effects generalized linear mixed model (GLMM) with a logit link. RESULTS: The combined searches identified 368 records; after deduplication, 255 records were screened, 72 reports underwent full-text assessment, and 50 eligible reports mapped to 42 study/cohort clusters. Six independent cohorts contributed 172 HE events among 1,047 patients, yielding a pooled HE proportion of 7.9% [95% confidence interval (CI), 2.8%-20.1%; τ = 1.19]. Following outcome-specific risk-of-bias reassessment, a sensitivity analysis excluding the two high-risk cohorts retained four studies (166 events among 865 patients) and yielded 12.1% (95% CI, 3.9%-32.0%; τ = 1.06). Across seven longitudinal cohorts, study-level blood eosinophil central estimates generally increased during the first 1-6 months and subsequently declined, while transient, persistent, repeated, and late-onset HE phenotypes were reported. Higher baseline eosinophil burden was the most consistent predictor signal, but no threshold was externally validated as a clinical decision rule. Permanent eosinophilia-related treatment modification occurred in 6/548 patients and severe eosinophilic organ complications occurred in 4/576 patients. Certainty of evidence was very low across prespecified domains. CONCLUSIONS: Treatment-emergent HE during dupilumab therapy for CRSwNP most often appears to represent a pharmacodynamic laboratory phenomenon, whereas permanent treatment modification and severe eosinophilic organ complications are uncommon in the available cohorts. Clinical interpretation should consider magnitude, temporal trajectory, persistence, associated symptoms, and evidence of organ involvement; standardized longitudinal monitoring is needed to improve ascertainment and identify the rare clinically consequential phenotype, although the evidence does not define a universal monitoring schedule.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.